From: Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients
 | SV | BV1 | V1 | BV2 | V2 | V3 | V4 | V5 | V6 | V7 |
---|---|---|---|---|---|---|---|---|---|---|
Day | -56 | -49 | -42 | 0 | 1 | 30 | 90 | 180 | 270 | 360 |
Time window | NA | ±3d | ±7d | ±1d | ±1d | ±7d | ±7d | ±7d | ±7d | ±7d |
Informed consent | x | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Physical examination | x | x | Â | x | Â | x | x | x | x | x |
Vital signs | x | x | x | x | Â | x | x | x | x | x |
Medical history | x | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Laboratory assessments | x | Â | Â | x | Â | x | x | x | x | x |
CBC | Â | Â | Â | x | Â | x | x | x | x | x |
BG | Â | Â | Â | x | Â | x | x | x | x | x |
NA, K, Ca, P | Â | Â | Â | x | Â | x | x | x | x | x |
BUN | Â | Â | Â | x | Â | x | x | x | x | x |
Uric acid | Â | Â | Â | x | Â | x | x | x | x | x |
Serum creatinine | x | Â | Â | x | Â | x | x | x | x | x |
eGFR | x | Â | Â | x | Â | x | x | x | x | x |
Albumin | Â | Â | Â | x | Â | Â | Â | x | Â | x |
TG, Chol, LDL,HDL | Â | Â | Â | x | Â | x | x | x | x | x |
FBS | x | Â | Â | x | Â | x | x | x | x | x |
HbA1c | x | Â | Â | Â | Â | Â | Â | Â | Â | x |
TSH, PTH | Â | Â | Â | x | Â | Â | Â | Â | Â | x |
ESR, CRP | Â | Â | Â | x | Â | x | x | x | x | x |
ALT, ALK-p, AST | Â | Â | Â | x | Â | x | x | x | x | x |
Dipstick proteinuria | Â | Â | Â | x | Â | x | x | x | x | x |
HIV 1,2, HCV, HBV, HTLV | x | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Eligibility criteria assessment | x | Â | Â | x | Â | Â | Â | Â | Â | Â |
Kidney sonography | Â | x | Â | Â | Â | Â | Â | Â | Â | x |
Kidney DTPA scan | Â | x | Â | Â | Â | Â | Â | Â | Â | x |
BM harvesting | Â | Â | x | Â | Â | Â | Â | Â | Â | Â |
MSC infusion | Â | Â | Â | Â | x | Â | Â | Â | Â | Â |
Follow-up visit | Â | Â | Â | Â | Â | x | x | x | x | x |
AE assessment a | Â | Â | Â | Â | x | x | x | x | x | x |
SAE assessment a | Â | Â | Â | Â | x | x | x | x | x | x |